Figure 2.

BLI of subcutaneous and metastasized MPC^LUC/GZ allografts in mice featuring different immunologic phenotypes; (A) metastatic spread at defined time points after cell injection; of note, images were individually scaled to 1/10 of the maximal luminescence intensity to also visualize small lesions, therefore, signal dimensions do not represent tumor size; (B) progression of luminescence intensities of subcutaneous tumors and metastases in vivo; logarithmic scaling of y-axis; (white data points, dotted lines) luminescence intensity of initially distributed tumor cells detected 32 min after subcutaneous and 20 min after intravenous cell injection (black data points, continuous lines) luminescence intensities of progressing tumors; depletion of natural killer (NK) cells resulted from treatment with anti-Asialo GM1 serum; the meaning of scattered metastases and disseminated metastases is given in the results section; (iv) intravenous, (sc) subcutaneous; ¹animal models showing reproducible pattern of metastases. A full colour version of this figure is available at https://doi.org/10.1530/ERC-18-0136.